---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-22-009206"
form_type: "8-K"
ticker: "OPRX"
cik: "0001448431"
company_name: "OptimizeRx Corp"
filed_at: "2022-02-24T23:59:59+00:00"
generated_at: "2026-06-27T04:44:13.392705+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# OptimizeRx Q4 revenue $20.3M (+24% YoY), FY revenue $61.3M (+42%), guides FY22 $80-85M

## Summary
- Q4 GAAP net income $0.6M ($0.04 diluted EPS); non-GAAP net income $4.0M ($0.22 diluted EPS).
- Gross margin improved to 61% in Q4 from 52.4% a year ago.
- Introduced KPIs: avg revenue per top-20 pharma client $2.5M, 95% penetration, net revenue retention 127%.
- FY22 guidance: revenue $80-85M (+31-39% YoY), gross margin 57-60%.
- Cash and equivalents $84.7M at Dec 31, 2021; cash flow positive from operations $0.7M in FY21.

## SEC filing metadata
- accession: 0001213900-22-009206
- form_type: 8-K
- ticker: OPRX
- cik: 0001448431
- company_name: OptimizeRx Corp
- filed_at: 2022-02-24T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1448431/000121390022009206/0001213900-22-009206-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1448431/000121390022009206/ea156150-8k_optimizerx.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-22-009206
- JSON: https://secwatch.observer/filing/0001213900-22-009206.json
- Plain text: https://secwatch.observer/filing/0001213900-22-009206.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.